首页> 外文期刊>Photodiagnosis and Photodynamic Therapy >Treatment of superficial basal cell carcinoma with photodynamic therapy. Observational study in 22 patients with 5-aminolaevulinic acid and methyl aminolaevulinate
【24h】

Treatment of superficial basal cell carcinoma with photodynamic therapy. Observational study in 22 patients with 5-aminolaevulinic acid and methyl aminolaevulinate

机译:具有光动力疗法的浅表基础细胞癌。 22例5-氨基乙酰乙酸和甲基氨基纤维素患者的观察性研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: There is limited literature on efficacy in 5-aminolaevulinic acid (BF-200 ALA) and methyl-5-aminolaevulinate (MAL) for superficial basal cell carcinoma (sBCC).Aims: To investigate the efficacy and safety of PDT in sBCC.Methods: Analytical observational study between January 2014 and January 2017. Follow-up at 12, 24 and 52 weeks. Lesions were treated with one BF-200 ALA-PDT or MAL-PDT cycle of two sessions in one week. A second treatment cycle, with the same photosensitizer precursor, was performed in cases of clinical persistence at 12 weeks.Results: A total of 22 patients (30 lesions) were enrolled in the study. By sex, 13 men and 9 women. Average age of 72,14 years. In the 12-month follow-up 15/16 lesions were resolved (93,75%) after one or two BF-200 ALA-PDT cycle and 7/14 lesions (50%) after one or two MAL-PDT cycles. In most patients, tolerance to the therapy was good or regular, with no differences between the two groups. No long-term adverse effects were reported.Limitations: The observational nature and the low number of patients.Conclusion: PDT is a safe and non-invasive treatment option in sBCC. Our results suggest a better response with BF-200 ALA-PDT over MAL-PDT, at 12 months of follow-up.
机译:背景:在浅表基础细胞癌(SBCC)中,5-氨基乙酰乙酸(BF-200 ALA)和甲基-5-氨基乙酰硫酸盐(MAL)有限的有限文献。探讨了PDT在SBCC中的疗效和安全性。方法:2014年1月至2017年1月的分析观测研究。在12,24和52周的后续行动。在一周内用一个BF-200 ALA-PDT或MAL-PDT循环处理病变。在12周的临床持久性的情况下,在临床持久性的情况下进行第二种治疗循环。结果:研究中共有22名患者(30例)。通过性,13名男子和9名女性。平均年龄为72,14岁。在12个月后续15/16后,在一个或两个BF-200 ALA-PDT循环和7/14病变(50%)后,解决了(93,75%),一次或两次MAL-PDT循环后的7/14病变(50%)。在大多数患者中,对治疗的耐受性好或常规,两组之间没有差异。没有报道长期不良反应。目的:观察性质和患者数量少。结论:PDT是SBCC中的安全和无侵入性治疗选择。我们的结果表明,在12个月的随访中,对MAL-PDT的BF-200 ALA-PDT进行了更好的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号